Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation - PubMed (original) (raw)

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation

Amy Tawfik et al. Clin Pharmacol. 2016.

Abstract

Background: In the last 4 years, four novel oral anticoagulants have been developed as alternatives to warfarin and antiplatelet agents for stroke prevention in atrial fibrillation (AF) patients. The objective of this review was to estimate the comparative effectiveness of all antithrombotic treatments for AF patients.

Materials and methods: Data sources were Medline Ovid (1946 to October 2015), Embase Ovid (1980 to October 2015), and the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 9, 2015). Randomized controlled trials of AF patients were selected if they compared at least two of the following: placebo, aspirin, aspirin and clopidogrel combination therapy, adjusted-dose warfarin (target international normalized ratio 2.0-3.0), dabigatran, rivaroxaban, apixaban, and edoxaban. Bayesian network meta-analyses were conducted for outcomes of interest (all stroke, ischemic stroke, myocardial infarction, overall mortality, major bleeding, and intracranial hemorrhage).

Results: Based on 16 randomized controlled trials of 96,826 patients, all oral anticoagulants were more effective than antiplatelet agents at reducing the risk of ischemic stroke and all strokes. Compared to warfarin, dabigatran 150 mg (rate ratio 0.65, 95% credible interval 0.52-0.82) and apixaban (rate ratio 0.82, 95% credible interval 0.69-0.97) reduced the risk of all strokes. Dabigatran 150 mg was also more effective than warfarin at reducing ischemic stroke risk (rate ratio 0.76, 95% credible interval 0.59-0.99). Aspirin, apixaban, dabigatran 110 mg, and edoxaban were associated with less major bleeding than warfarin.

Conclusion: All oral anticoagulants reduce the risk of stroke in AF patients. Some novel oral anticoagulants are associated with a lower stroke and/or major bleeding risk than warfarin. In addition to the safety and effectiveness of drug therapy, as reported in this study, individual treatment recommendations should also consider the patient's underlying stroke and bleeding risk profile.

Keywords: atrial fibrillation/prevention and control; cerebrovascular disorders/drug therapy; meta-analysis; platelet-aggregation inhibitors; stroke prevention.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the study-selection process. Abbreviations: RCTs, randomized controlled trials; MTC, multiple-treatment comparison.

Figure 2

Figure 2

Network of evidence. Notes: (A) Base-case multiple-treatment comparison analysis; (B) sensitivity analysis. The nodes represent the choice of stroke prophylactic treatment and the lines connecting the nodes represent direct comparisons from randomized controlled trials. The diameter of the nodes represents the number of patients receiving the intervention; the width of the lines and the numbers next to them indicate the number of direct comparisons. Abbreviations: ASA, acetylsalicylic acid (aspirin); APX, apixaban; C, clopidogrel; DAB 110, dabigatran 110 mg; DAB 150, dabigatran 150 mg; EDX HD, high-dose edoxaban; EDX LD, low-dose EDX; RVX, rivaroxaban; WAR, warfarin.

Figure 3

Figure 3

Ranking distributions of each treatment for ischemic stroke (efficacy) and major bleeding (safety). Notes: Distributions based on 100,000 Markov chain Monte Carlo simulations. Ranking indicates the probability that a treatment is ranked first (best) to tenth (worst) with respect to both outcomes. Abbreviations: LD, low dose; HD, high dose.

Similar articles

Cited by

References

    1. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167:2412–2420. - PubMed
    1. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anti-coagulated. Stroke. 2009;40:235–240. - PubMed
    1. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–136. - PubMed
    1. Camm AJ, Lip GY, De Caterina R, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747. - PubMed
    1. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442–3453. - PubMed

LinkOut - more resources